What type of study is this?

October 23, 2025Open Access

Clinical outcomes of long‐acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real‐world data from the Spanish RELATIVITY cohort

Key Points

Virological suppression rates remained high at 97.3% in older adults with HIV after 15 months of follow-up.
Among 370 older participants, discontinuation rates were 7.8% and adverse events 1.6%, showing minimal differences from younger adults.
Ambispective real-world analysis using Kaplan–Meier and Cox models was conducted on a cohort aged ≥60 years.
These findings support long-acting therapy in geriatric HIV care despite challenges like multi-morbidity.

Abstract

Abstract Background Long‐acting injectable cabotegravir and rilpivirine (LAI CAB + RPV) is an established maintenance strategy for people with HIV who are virologically suppressed, providing high efficacy and convenience in treatment. However, evidence in older adults (≥60 years), a growing and complex population, is limited. Methods We conducted an ambispective real‐world sub‐analysis of the Spanish RELATIVITY cohort, including people with HIV aged ≥60 years who initiated LAI CAB + RPV across 58 centres. Outcomes (virological suppression, safety, discontinuation and adherence) were compared with those 89% of the participants aged ≥60 years demonstrating perfect adherence. Conclusion In this large multicentre real‐world sub‐study, LAI CAB + RPV maintained virological control and showed good tolerability in older people with HIV despite high multi‐morbidity and long‐term ART exposure. These findings extend the evidence from previous trials and support LAI CAB + RPV as a feasible option for geriatric HIV care. Longer follow‐up will provide further insights into durability and quality‐of‐life benefits.

Clinical outcomes of long‐acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real‐world data from the Spanish RELATIVITY cohort

Key Points

Abstract

Cite This Study